Back to Archived Journals » Biosimilars » Volume 6

Physicochemical and biological comparison of the first Brazilian biosimilar filgrastim with its reference product

Authors Mantovani M, Caruso C, Facchini F, Pascon R, Cagnacci P, Magalhaes V

Received 6 March 2016

Accepted for publication 28 April 2016

Published 30 August 2016 Volume 2016:6 Pages 45—60


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 4

Editor who approved publication: Professor Shein-Chung Chow

Monique Mantovani,1,2 Cecilia Sulzbacher Caruso,1 Fernanda Dell Antonio Facchini,1 Renata Pascon,1,3 Patrícia Ribeiro Vilaça Cagnacci,1 Vanda Dolabela de Magalhães1

1Department of Biotechnology, Eurofarma Laboratórios SA, São Paulo, SP, Brazil; 2Libbs Farmacêutica Ltda, Embu das Artes, SP, Brazil; 3Department of Biological Sciences, Federal University of São Paulo, Diadema, SP, Brazil

Abstract: The registration of biosimilars requires comparison studies to reference products to guarantee their safety, purity, efficacy, and potency. In this study, we demonstrate the similarity of a filgrastim produced by Eurofarma (Fiprima®) and one produced by Amgen Inc. (commercialized by Hoffman-La Roche Ltd, Granulokine®) in terms of drug identity, structure, purity, and bioactivity. The methods used to compare both products were the following: peptide mapping, bidimensional electrophoresis, reduced and nonreduced polyacrylamide electrophoresis, Western blotting, reverse-phase high-performance liquid chromatography, size-exclusion high-performance liquid chromatography, far and near circular dichroism, fluorescence emission, X-ray crystallography, liquid chromatography–tandem mass spectrometry, matrix-assisted laser desorption/ionization-time of flight, receptor binding, and potency by in vitro cell proliferation. Biosimilarity to Granulokine was demonstrated in terms of identity, structure, purity, and bioactivity.

Keywords: filgrastim, biosimilar, biopharmaceutical, G-CSF, comparability, neutropenia

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]